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Abstract
Objective: We explored whether financial incentives have a role in patients9 decisions to accept (purchase) a continuous
positive airway pressure (CPAP) device in a healthcare system that requires cost sharing.
Design: Longitudinal interventional study.
Patients: The group receiving financial incentive (n=137, 50.8610.6 years, apnea/hypopnea index (AHI) 38.7619.9 events/
hr) and the control group (n=121, 50.9610.3 years, AHI 39.9622) underwent attendant titration and a two-week
adaptation to CPAP. Patients in the control group had a co-payment of $330–660; the financial incentive group paid a
subsidized price of $55.
Results: CPAP acceptance was 43% greater (p=0.02) in the financial incentive group. CPAP acceptance among the low
socioeconomic strata (n=113) (adjusting for age, gender, BMI, tobacco smoking) was enhanced by financial incentive (OR,
95% CI) (3.43, 1.09–10.85), age (1.1, 1.03–1.17), AHI (.30 vs. ,30) (4.87, 1.56–15.2), and by family/friends who had positive
experience with CPAP (4.29, 1.05–17.51). Among average/high-income patients (n=145) CPAP acceptance was affected by
AHI (.30 vs. ,30) (3.16, 1.14–8.75), living with a partner (8.82, 1.03–75.8) but not by the financial incentive. At one-year
follow-up CPAP adherence was similar in the financial incentive and control groups, 35% and 39%, respectively (p=0.82).
Adherence rate was sensitive to education (+yr) (1.28, 1.06–1.55) and AHI (.30 vs. ,30) (5.25, 1.34–18.5).
Conclusions: Minimizing cost sharing reduces a barrier for CPAP acceptance among low socioeconomic status patients.
Thus, financial incentive should be applied as a policy to encourage CPAP treatment, especially among low socioeconomic
strata patients.
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Introduction
Continuous positive airway pressure (CPAP) is the treatment of
choice for obstructive sleep apnea (OSA) [1–6]. CPAP is the most
effective and cost-effective treatment for OSA when compared
with conservative/usual care and placebo [7–10]. If used on a
regular basis, CPAP can effectively decrease daytime sleepiness [3–
5,8], reduce cardiovascular morbidity [6,11–13] and health care
utilization [14]. Yet many patients, mainly of lower socioeconomic
(SES) background, do not accept (purchase the device) CPAP in a
healthcare system that requires cost sharing [15,16]. Factors
influencing CPAP acceptance are multi-factorial and include
awareness, physician involvement, support programs, spouse
involvement, and health care system policies [3,15–24]. Despite
the increase in CPAP treatment options (i.e., bi-level positive
airway pressure, auto-adjusting CPAP), treatment acceptance and
adherence are low. It has been estimated that 15–30% of patients
do not accept CPAP treatment from the outset [5,24]. Patients
with low SES background are less likely to commence CPAP
treatment [16]. Low SES per se has been identified as a barrier to
diagnosis in many previous studies outside the field of sleep [25–
27]. When OSA patients were offered CPAP treatment in a health
system that provides free access to diagnosis and titration studies,
the effect of SES as the range of income is not truncated by limited
access to care. Under circumstances where access to diagnosis is
not limited, SES plays a role in the patient9s decision on whether
to pursue a treatment in a health system that requires cost sharing
[15,16]. The CPAP device is relatively expensive; many low-
income patients view this aspect of healthcare as an unnecessary
expense and only 40% of those recommended for CPAP accept
the treatment. For each increase in income level category, the odds
for CPAP acceptance increased by 140% [16]. Patients that accept
CPAP are older, have higher SES level, severe apnea, no bed
partner, and heard about positive CPAP experiences from family
and friends [15,16].
Cost sharing (or co-payment) is an accepted expenditure-control
strategy. It reduces the ‘‘moral hazard’’ phenomena (i.e.,
individuals with health insurance will overuse health services
because they bear no portion of the financial burden) to lower
consumer demand in every health care system studied [28]. On
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medications [28–32] and to increased use of emergency
department visits and hospital days [28,30,32]. Such cost-related
restriction could be a mechanism for worse health outcomes
among low-income and other vulnerable populations who lack
adequate insurance coverage [29]. In order to balance the
demands for access to pharmaceuticals with pressures to constrain
costs, levels of cost sharing must be set in a manner that achieves
appropriate clinical and financial outcomes. Financial incentive
polices in the health care system has been proposed as a strategy to
promote high-value health care based on the potential for clinical
benefit [33,34] and minimize health risk-behavior [33–36].
Little is known about the effect of financial incentive policy on
CPAP acceptance in a health care system that uses cost-sharing
strategy. We hypothesized that providing a financial incentive will
overcome the barrier of cost, increasing CPAP acceptance mainly
among low SES OSA patients. In this study we explored the effect
of financial incentive on OSA patients9 decisions to accept CPAP
treatment in a healthcare system that requires mandatory cost
sharing.
Methods
Study design
Longitudinal interventional study, time block randomization
protocol (to adjust for time-dependent effects), beginning February
2009 for 24 months.
Participants
We recruited symptomatic adult OSA patients in the working
age range (ages #25 –,68 years, naı ¨ve to CPAP), requiring CPAP
treatment [2]: apnea hypopnea index (AHI) $30 (events/hour) or
an AHI $15 (events/hour) accompanied by symptoms of
excessive daytime sleepiness according to an Epworth Sleepiness
Scale (ESS) score $10 [37], and/or documented cardiovascular
disease/hypertension. We excluded patients with mild OSA,
requiring bi-level pressure, or language comprehension difficulties.
The Human Subject Committee of Soroka University Medical
Center approved protocol number 10262. Written informed
consent was obtained from all patients. CPAP acceptance was
determined at the conclusion of the adaptation period, using
downloaded data from CPAP devices to confirm objective CPAP
use.
Cost sharing
To initiate CPAP treatment patients were required to pay a
mandatory out-of-pocket co-payment, according to the National
Health Insurance Law. Cost sharing is 25–50% of CPAP cost
(average cost of a CPAP device was $1320), depending on the
patient9s supplementary health insurance coverage. Patients in the
control group were required to pay the full cost sharing for the
CPAP treatment in the range of $330 to $660, depending on their
supplementary medical insurance coverage. The financial incen-
tive group was offered CPAP at a subsidized price of $55, i.e., the
ceiling for monthly out-of-pocket expenditure for drugs in patients
with chronic diseases in Israel (drug expenditure above this ceiling
is reimbursed according to the law). In cases where auto-titrating
CPAP was purchased, patients were required to pay the difference
(Methods S1).
Socioeconomic status
Socioeconomic status classified by the researchers to one of
three categories, according to self-reported monthly income: below
(,20%), equal to (620%), or above (.20%) the average monthly
gross income level in Israel. The lowest group was defined as
belonging to the low SES strata [15,16,26].
Procedures and Questionnaires
Initially, the control group was recruited (n=93), followed by
the financial incentive (n=137) group (Figure 1). To adjust for
time, 28 (30%) additional control subjects were recruited at the
conclusion of the study. Thus, the final control group included 121
patients. All patients underwent similar protocol treatment and
data handling. During the diagnostic and therapeutic process
patients completed a variety of questionnaires [26,37,38]. A
telephone survey was conducted one year following CPAP
treatment initiation, to collect the following information: self-
reported CPAP use (hours per night, days per week), ESS score,
CPAP side effects score [39], reasons for using or declining CPAP,
and social support.
Overnight PSG. Overnight PSG was performed according to
previously described methods [26]. Subjects reported to the
laboratory at 8:30 PM and were discharged the following
morning; they were encouraged to maintain their usual daily
routine and to avoid any caffeine and/or alcohol intake on the day
of the study. Shift workers did not perform the PSG study in the
week following shift duty. Upon receiving results of the CPAP
titration study, sleep specialists encouraged patients to undergo a
mandatory two-week adaptation period in order to commence
treatment, and were informed that if they will accept (will regularly
use CPAP) this treatment it will require out-of-pocket payment,
according to the Israel National Health Insurance Law. In the case
of the incentive group, the out-of-pocket payment was subsidized
by the study. CPAP titration was performed two weeks following
PSG using attendant auto-titration CPAP without concomitant
PSG monitoring.
CPAP support
A two-week period of adaptation with an auto-titrating CPAP
device at home was encouraged [16,21]. Patients were encouraged
to try a variety of masks and CPAP manufacturers free of charge.
At the conclusion of the CPAP support patients were offered the
purchase of regular or auto-titrating CPAP (from a variety of
manufacturers) as needed, they completed CPAP usage side effects
[39], knowledge, and apnea beliefs scale [40], and reasons for
CPAP acceptance or non-acceptance questionnaires [16].
Data and statistical analysis
Data were analyzed using SPSS v17 Software (IBM Corpora-
tion, Somers, NY). Logistic regression analysis was used to
Figure 1. Flow chart showing stages of the diagnostic and
therapeutic process and number of patients at each stage.
doi:10.1371/journal.pone.0033178.g001
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hypothesis was rejected at the 5% level (see Methods S1).
Results
Patients
158 and 137 patients in the financial incentive and control
groups, respectively, met the inclusion criteria (Figure 1). Sixteen
patients in the control group and 21 in the financial incentive
group refused to be included in this study, and were excluded. The
characteristics of the additional 28 control group patients recruited
at the conclusion of the study were similar to the 93 subjects
recruited at the beginning of the study by income level (p=0.215),
age (p=0.404), gender (p=0.667), AHI (p=0.176), BMI
(p=0.867), and percent of subjects accepting CPAP (p=1.00).
No significant differences were found between financial
incentive and control groups9 characteristics, supplementary
health insurance coverage, and OSA severity except for tobacco
smoking (p=0.003), percent of sleeping time in which oxygen
saturation was below 90% (T90%, p=0.04), which were higher in
the control group (Table 1). Side effects score was similar among
smoking and non-smoking patients requiring CPAP (p=0.319).
Smoking history did not affect the decision to accept CPAP in
either group (p=0.489).
The number of subjects #40 years old was similar (p=0.326) in
both groups, 24/137 (17.5%) and 22/121 (18.2%), respectively.
Thirty-three percent (n=40) and 47% (n=65) in the control and
financial incentive groups, respectively, accepted CPAP (p=0.02;
Table 1). The proportion of patients accepting CPAP among
young adults was lower in both the control and incentive groups
[5/22 (22%) and 6/24 (25%), respectively] compared with the
entire group CPAP acceptance rate. Twenty-three percent and
29% (p=0.502) in the control and incentive groups, respectively,
reported that they received positive information from family and/
or friends treated with CPAP, compared with 14.8% and 28.2%
(p=0.049) of CPAP-declining patients in the control and incentive
groups, respectively. The characteristics of patients accepting and
declining CPAP in the incentive and control groups are
summarized in Table 2. Among patients who purchased CPAP,
a greater proportion of low SES patients was found in the
incentive group compared to the control group, 53.8% vs. 30%,
respectively (p,0.01). Among those who accepted CPAP, 25%
and 28% of the patients in the control and incentive groups,
respectively, purchased auto-titrating CPAP and the remainder
purchased the standard device. Similar CPAP pressure and post-
treatment AHI were found in patients declining CPAP compared
with patients accepting a regular CPAP device in both the control
and financial incentive groups (Table 2). Similar side effects score,
apnea knowledge, and apnea belief scale were found in both the
control and incentive groups. In both groups, upon completion of
the CPAP support patients declining CPAP experienced a greater
side effect score (values are median and range) than patients
accepting CPAP, 17 (0–63) vs. 7 (0–63), respectively (p,0.001).
Patients declining CPAP reported less apnea knowledge compared
with patients accepting CPAP 5 (0–20) vs. 6 (0–20) respectively
(p=0.021) and reported a lower apnea belief scale 73 (24–120) vs.
89 (24–120) respectively (p,0.001). Common reasons for CPAP
acceptance among the control and incentive groups were: solving
snoring problems (81.8% vs. 85.5% of the respondents, p=0.737),
reducing daytime sleepiness (72.7% vs. 78.1%, p=0.575),
encouragement by their partner (54.5 vs. 54.7%, p=1.0),
improving sleep (45.5% vs. 57.8%, p=0.333), and ‘‘It is the best
treatment available’’ (31.8% vs. 56.3%) respectively (p=0.082),
respectively. Common reasons for declining CPAP treatment
among control and incentive groups were: ‘‘could not adapt’’
(100% vs. 95.2%, p=1.0), ‘‘side effects’’ (75% vs. 66.7%, p=1.0),
and ‘‘CPAP cost is too expensive for me’’ (50% vs. 4.8%)
respectively (p=0.013).
Compared with average/high income patients, low-income
patients included more women (p=0.005), fewer patients living
with a partner (p=0.01), fewer years of education (p=0.001), and
a trend for higher BMI (p=0.06) (Table 3). Odds for cardiovas-
Table 1. Comparison of control and incentive groups.
Control group (n=121) Incentive group (n=137) P
CPAP acceptance (%) 33.1 47.4 0.02
Males (%) 79.3 78.8 1.0
Age (years) 50.9610.3 50.8610.6 0.95
BMI (kg/m
2)3 2 . 1 66.7 32.665.6 0.59
AHI (events/h) 39.9622.0 38.7619.9 0.62
T90 (%) 11.9618.8 7.5615.2 0.04
ESS (score) 10.164.9 10.265.3 0.89
Tobacco smoking (pack/year) 23.6626.6 13.2624.3 0.003
Education (years) 13.263.7 13.563.0 0.58
HTN/CVD (%) 48.8 51.8 0.71
Living with a partner (%) 86.8 85.4 0.86
Employed (%) 71.1 75.2 0.48
Income level
Low (%) 40.5 46.7 0.16
Average (%) 43.0 44.5
High (%) 16.5 8.8
AHI – Apnea-Hypopnea Index, BMI – Body Mass Index, CPAP accepting – patients who purchased CPAP and commence treatment. CVD – cardiovascular disease, ESS –
Epworth Sleepiness Scale, HTN – hypertension, T90 – percent sleeping time in which oxygen saturation was below 90%. Values are mean6SD.
doi:10.1371/journal.pone.0033178.t001
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low-income patients (Table 3).
Effects of financial incentive on CPAP acceptance
Multivariable logistic regression (adjusting for income level,
gender, BMI, T90%, ESS, tobacco smoking) revealed that CPAP
acceptance was determined by (OR, CI% 95) age (yr +1) (1.033,
1.004–1.064), AHI (30 vs. ,30) (2.6, 1.325–4.967), and low
income*financial incentive (2.9, 1.03–8.19); area under the ROC
curve was 71.2%.
To explore the impact of financial incentive on CPAP
acceptance, a multivariable regression analysis was performed
Table 2. Characteristics of patients declining and accepting CPAP in the control and Incentive groups.
Control group Incentive group
Declined CPAP (N=81,
66.9%)
Accepted CPAP (N=40,
33.1%)
Declined CPAP (N=72,
52.6%)
Accepted CPAP (N=65,
47.4%)
Males (%) 74.1 90.0 80.6 76.9
Age (years) 51.1611.8 50.368.3 47.1610.1 54.469.9
{
BMI (kg/m
2) 31.266.5 32.564.8 31.265.3 33.565.4
AHI (events/hour) 37.3620.1 45.3623.4* 36.1620.5 41.5619.1*
ESS (score) 9.964.8 10.364.9 10.765.3 9.565.3
Tobacco Smoking (pack/year) 22.8624.7 25.5628.1 9.7619.7 17.0628.2
{
HTN/CVD prevalence (%) 50.6 45.0 47.2 56.9
Live with Partner (%) 84.0 92.5 84.7 86.2
Income (low, average/high)
Low (%) 45.7 30.0 40.3 53.8+
Average/High (%) 54.3 70.0 59.7 46.2+
CPAP pressure (cmH2O) 8.462.6 9.062.4 8.262.2 8.762.8
AHI on CPAP (events/hour) 5.262.3 5.362.5 5.262.7 3.362.8
AHI – apnea-hypopnea index, BMI – body mass index, CPAP – continuous positive airway pressure, CVD – cardiovascular disease, ESS – Epworth Sleepiness Scale, HTN –
hypertension, Income – individual monthly income relative to average monthly income level in Israel.
*p,0.05,
{p,0.001 comparing CPAP declined with CPAP accepting in each group.
{p,0.05 comparing CPAP accepting patients in the control and incentive groups.
+p,0.05 comparing CPAP accepting and CPAP declined in the incentive group.
Values are mean6SD.
doi:10.1371/journal.pone.0033178.t002
Table 3. Patient Characteristics According to Income Level.
Low Income (N=113) Average/High Income (N=145) PV
Age (years) 51.8610.5 50.1610.4 0.2
Men (%) 70.8 85.5 0.005
BMI (kg/cm
2)3 3 . 2 6 7.2 31.7 6 5.2 0.06
AHI (events/hr) 37.4620.8 40.7620.9 0.22
T90 (%) 10.2620.9 9.0613.3 0.60
ESS (score) 10.765.4 9.764.8 0.11
Living with Partner (%) 79.6 91.0 0.01
Tobacco smoking (pack/years) 16.3624.5 17.9626.3 0.64
Education (years) 11.963.2 14.463.1 ,0.001*
Education$12 years (%) 60.6 92.4 ,0.001*
Co-morbid diagnoses Prevalence Prevalence OR (95% CI)
CVD (%) 57.5 44.8 1.67 (1.01–2.74)
HTN (%) 55.1 43.1 1.62 (0.78–3.37)
Hyperlipidemia (%) 57.1 37.5 2.22 (1.06–4.66)
Diabetes (%) 18.4 9.7 2.09 (0.72–6.05)
AHI – Apnea-Hypopnea Index, BMI – Body Mass Index, CVD – Cardiovascular Diseases, ESS – Epworth Sleepiness Scale, FOSQ – Functional Outcomes of Sleep
Questionnaire, HTN – Hypertension, T90 – percent sleeping time in which oxygen saturation was below 90%. Values are mean6SD.
doi:10.1371/journal.pone.0033178.t003
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patients (Table 4). For low-income patients (adjusting for age,
gender, BMI, living with partner, tobacco smoking) CPAP
acceptance was sensitive to financial incentive (y/n) (3.43, 1.09–
10.85),age (1.1, 1.03–1.17), AHI (30 vs. ,30) (4.87, 1.56–15.2), and
family/friends having positive experience with CPAP (y/n) (4.27,
1.05–17.51); area under the ROC curve of 81%. Adjusting for side
effects score, apnea belief scale, and apnea knowledge score did not
affect our findings that financial incentive is an independent
predictor of CPAP acceptance among low-income patients. Among
average/high-income patients CPAP acceptance was sensitive to
AHI (30 vs. ,30) (3.16, 1.14–8.75) and living with partner (y/n)
(8.82, 1.03–74.8); area under the ROC curve 69.3%. T90% was
associated with AHI and smoking (p,0.001); education and
smoking were associated with income level (p,0.001), and
cardiovascular disease/hypertension prevalence was associated with
age (p=0.003). Therefore, they were not included in the model.
CPAP adherence
At one-year follow-up CPAP adherence (CPAP usage .4
hours/night, $6 day/week) was similar in the financial incentive
and control groups, 35% and 39%, respectively (p=0.82). Odds
for CPAP adherence at one-year follow up among the financial
incentive group were similar to the control group (0.86, 0.36–
2.07). Multivariable analysis (adjusting for financial incentive,
income level, age, gender, and tobacco smoking) revealed that the
CPAP adherence at one year was sensitive to years of education
(+1yr) (1.28, 1.06–1.55) and AHI (30 vs. ,30) (5.25, 1.34–18.5),
area under the ROC curve of 76.1%.
Discussion
Financial incentive was associated with greater likelihood of
CPAP acceptance among low-SES OSA patients in a health care
system using a cost sharing strategy to contain costs. Therefore, we
suggest that financial incentive should be applied as a policy to
encourage CPAP acceptance, especially among low SES patients.
Study strength and limitation
According to the Israeli National Health Insurance Law, all
patients have free of charge access to PSG and CPAP titration
studies [16,26,41,42]. Both the control and financial incentive
groups were recruited using a longitudinal study design. One
possible shortcoming of our study was that we were not allowed by
our Institutional Review Board to perform randomization of
patients to groups and conduct a parallel study design, because
patients were recruited during routine PSG study. We believe that
this possibility of shortcoming is low, since both control and
incentive groups were identical in all parameters (Table 1) except
for tobacco smoking and T90%. Accordingly, our model was
adjusted for tobacco smoking, which may be taken as a surrogate
for poor health behavior. Moreover, similar CPAP pressure, AHI
on CPAP, and side effects scores were found in the control and
incentive groups. An additional possible limitation could be the
self-reported income of the patient, particularly if individual
income does not reflect overall household income, which may be
more representative of SES. Finally, models were adjusted for
time-dependent factors (time block) by recruiting additional 28
(30%) subjects who were found to be similar in all parameters to
the 93 control subjects recruited at study initiation. In both groups,
upon completion of the CPAP support patients declining CPAP
experienced a greater side effects score. Multivariable logistic
regression analysis revealed that financial incentive was an
independent predictor of CPAP acceptance among low-SES
patients.
In both groups, CPAP purchase was about 40% lower in young
adult (#40 years) OSA patients relative to older patients. In young
adults with OSA, the prevalence of hypertension and cardiovas-
cular disease is lower [41,43]. It is possible that young adults with
OSA will be less determined to commence CPAP when no
symptoms exist, and they may seek other therapeutic options. In
addition, clinicians9 attention and awareness preclude recom-
mending CPAP treatment at younger ages [41].
Cost incentive and CPAP treatment
To our knowledge this is the first study exploring the effect of
financial incentive on patients9 acceptance of CPAP technology. In
our study CPAP acceptance rates were unacceptably low, and only
one-third of patients in the control group accepted the CPAP,
supporting our previous findings [15,16]. This result is in contrast
to other reports demonstrating that when receiving support
protocol, CPAP acceptance is about 70% [20,21]; possible
Table 4. Determinants of OSAS Patients Accepting CPAP Treatment among Low Income and Average/High Income Strata.
Variable Low Income (N=113) Average/High Income (N=145)
OR 95% CI Pv OR 95% CI Pv
Financial Incentive (yes vs. no) 3.43 1.09–10.85 0.036 1.07 0.44–2.61 0.882
Age (+1 year) 1.10 1.03–1.17 0.002 1.02 0.98–1.06 0.469
BMI (+1) 1.02 0.95–1.10 0.539 0.99 0.92–1.09 0.950
AHI ($30 vs. ,30) 4.87 1.56–15.2 0.006 3.16 1.14–8.75 0.027
Gender (male vs. female) 0.43 0.13–1.43 0.168 0.87 0.22–3.35 0.842
Family and/or friends have positive experience with
CPAP (yes vs. no)
4.29 1.05–17.51 0.042 1.11 0.45–2.73 0.827
Living with Partner (yes/no) 0.33 0.08–1.29 0.110 8.82 1.03–75.8 0.047
Tobacco Smoking (+1 packs years) 1.01 0.99–1.03 0.461 1.01 0.99–1.02 0.631
High Income (vs. Average Income) 0.36 0.12–1.05 0.062
AHI – apnea-hypopnea index, BMI – body mass index, CPAP – continuous positive airway pressure, CVD – cardiovascular disease, ESS – Epworth Sleepiness Scale,
Financial Incentive – received financial support, HTN – hypertension.
Area under the ROC 81.0% and 69.3% for low income and average/high income patients, respectively.
doi:10.1371/journal.pone.0033178.t004
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zation of cost sharing to $55 increases CPAP acceptance by
43.2%. Only 4.8% vs. 50% (p=0.013) from the incentive and
control groups, respectively, refused treatment claiming that cost
was a substantial factor determining their decision. From an
economic point of view, cost sharing is an administrative tool
aimed to reduce health care costs and to prevent moral hazard.
This policy may unfairly discourage people from seeking essential
medical services and medication [28–30]. In practice, cost sharing
is rarely linked to the service9s value [26,28–32,44] including
CPAP [15,16] especially among lower SES populations. In a chart
review study, 42% of patients from minority-serving institutions
diagnosed with OSA failed to follow up for treatment despite
having medical insurance coverage for CPAP, compared with 7%
in a voluntary hospital group [45]. Similar findings were reported
among other urban patient populations [39,46]. In low SES
patients, CPAP purchase is low, despite having medical insurance
for OSA diagnosis and CPAP titration study; it is possible that
these patients are less knowledgeable about their disease and its
treatment options [39,45,46]. Financial incentive was found to be
an effective tool in minimizing health risk-behavior, particularly
among low-SES people [33,34,47]. Implementing a large value-
based insurance design program as offered by Blue Cross Blue
Shield of North Carolina [48] and by a large employer9s value-
based insurance [49], increases adherence rate to chronic essential
medication. Not surprisingly, disease management per se was not
sufficient to overcome the barrier of co-payment [49]. In our study
adherence to CPAP one year after accepting a device was similar
in both groups. Our findings support the notion that no single
factor has been consistently identified as predictive of CPAP
acceptance and adherence [3,15,16,22,24]. Understanding obsta-
cles and critical elements associated with a patient9s decision to
accept CPAP is crucial to promote successful treatment adherence.
This includes optimal disease management, which improves
patients9 attitudes, beliefs, and expectations about OSA and its
treatment [17,22–24,50] in addition to minimizing cost sharing for
CPAP.
In our study, AHI was an independent predictor that increased
the odds for CPAP acceptance. Other studies have demonstrated
that AHI has a weak relationship with CPAP treatment
acceptance [3], mainly in symptomatic patients. It is possible that
primary care physician recommendations to commence CPAP are
based on AHI. However, Brin et al. [15] found a CPAP purchase
rate of 35% after analyzing the subgroup of the most severe and
symptomatic patients. It is possible that policy criteria only
including AHI may affect physician recommendations to com-
mence CPAP. The current study confirms Simon-Tuval9s [16]
findings indicating that the primary care physician impact on
patient decision to accept CPAP was probably minimal, i.e., our
patients reported that little information was obtained from their
physicians regarding therapeutic options. It is possible that the
average/high-income patients did not respond to this change in
cost-sharing policy since the amount of money saved in our cost
sharing policy was negligible relative to their income level, and
they may interpret this financial incentive as a means to encourage
them to use an unneeded therapy [34].
Cost sharing is not a one-size-fits-all tool; it may be appropriate
when health services are of low value and inappropriate when
health services are of high value [34], as in the case of CPAP
treatment. In Israel, co-payment is high and widely used across
essential and non-essential treatments [30]. Our study suggests
that adapting a more benefit-based cost sharing34 will provide a
financial incentive for individuals to prioritize their out-of-pocket
expenditures based on the value of their treatments, not their
price. As a result, more balanced expenditure-control strategy will
increase demand and will minimize discrimination of a vital health
care service, mainly among vulnerable populations [34,51,52].
Conclusions
Minimizing cost sharing reduces a major barrier for CPAP
acceptance among low SES patients with OSA. Implementation of
value-based cost sharing strategy for acceptance of a CPAP device
would provide a positive financial incentive for patients with OSA
to prioritize the option of CPAP treatments as a high-value care
based on its potential clinical benefit.
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